Advocacy intelligence hub — real-time data for patient organizations
Bronchitol®: FDA approved
as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use Bronchitol only for adults who have passed the Bronchitol Tolerance Test.
Ravicti: FDA approved
Use as a nitrogen-binding agent for chronic management of adult and pediatric patients > or =2 years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (eg, essential amino acids, arginine, citrulline, protein-free calorie supplements).
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Ravicti
Horizon Therapeutics USA, Inc.
Browse all OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk news →
View all OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk specialists →